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Abstract
Heparan sulfate (HS) is a sulfated polysaccharide exhibiting essential physiological functions. HS 
6-O-sulfotransferase (6-OST) transfers a sulfo group to the 6-OH position of glucosamine units to 
confer a variety of HS biological activities. There are three different isoforms of 6-OST in the 
human genome. Here, we report crystal structures of the ternary complex of 6-OST with the sulfo 
donor analog 3′-phosphoadenosine 5′-phosphate and three different oligosaccharide substrates at 
1.95 to 2.1 Å resolutions. Structural and mutational analyses reveal amino acid residues that 
contribute to catalysis and substrate recognition of 6-OST. Unexpectedly, the structures reveal 6-
OST engages HS in a completely different orientation than other HS sulfotransferases, and sheds 
light on the basic HS requirements for specificity. These findings also contribute structural 
information to understand mutations in human 6-OST isoform 1 associated with the human 
genetic disease idiopathic hypogonadotrophic hypogonadism characterized by delayed or lack of 
puberty.
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Heparan sulfates (HS) are sulfated polysaccharides that are found on the surface of 
mammalian cells attached to core syndecan and glypican proteins and are secreted into the 
extracellular matrix, associated with perlecan, agrin and collagen XVIII1, 2. HS contains a 
disaccharide repeating unit of glucuronic acid (GlcA) or iduronic acid (IdoA) and 
glucosamine (GlcN). Both IdoA and GlcN are capable of carrying sulfo groups, while GlcA 
can be sulfated to a lesser extent. HS play important roles in a wide range of physiological 
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and pathophysiological functions including assisting in viral/bacterial infection, 
inflammatory responses, blood coagulation, angiogenesis, and embryonic development3. 
Notably, HS is implicated in the formation of amyloid plaques contributing to Alzheimer's 
disease4. HS carry out their wide range of functions through interactions with proteins such 
as growth factors, protease inhibitors, proteases, cytokines, chemokines and 
morphogens1, 2, 5. Many of these interactions rely on distinctive sulfated saccharide 
sequences in HS for high specificity.
The HS 6-O-sulfotransferase isoforms (6-OSTs) are members the HS biosynthetic enzyme 
family that transfer a sulfo group from 3′-phosphoadenosine 5′-phosphosulfate (PAPS) to 
the 6-OH of GlcN. HS biosynthesis occurs in the Golgi and endoplasm reticulum and 
involves glycosyltransferases, an epimerase and several sulfotransferases. A backbone 
polysaccharide with a disaccharide repeating unit of GlcA and N-acetyl glucosamine (-
GlcA-GlcNAc-) is initially synthesized by HS polymerase. The backbone polysaccharide 
then undergoes a series of modifications (Supplementary Figure 1)6. In general, modification 
begins with N-deacetylation/N-sulfation by the N-deacetylase/N-sulfotransferases (NDSTs) 
to convert GlcNAc residues to N-sulfo GlcN (GlcNS) residues. This modification allows for 
C5-epimerization of neighboring GlcA residues to form an IdoA residue, followed by 
sulfation at the 2-OH by the 2-O-sulfotransferase (2-OST). HS is further modified by 6-O-
sulfation on GlcNS/GlcNAc residues by 6-OSTs. The final modification step involves the 
introduction of 3-O-sulfo groups on GlcN residues by 3-O-sulfotransferases (3-OSTs). The 
crystal structures of several members of the HS biosynthetic enzymes have been solved, 
including the N-sulfotransferase domain of NDST-1, 2-OST, 3-OST (isoforms 1,3 and 5) 
and C5-epimerase7–13. The structural information, especially those complexes with bound 
oligosaccharide substrates, has revealed the mechanisms used by different enzymes to 
recognize saccharide residues in HS. Until now, the crystal structure of 6-OST has remained 
elusive.
6-O-sulfation participates in a wide range of biological functions and has been associated 
with a variety of human diseases. In particular, 6-O-sulfation is required for the formation of 
a ternary complex between fibroblast growth factor (FGF)/HS and the fibroblast growth 
factor receptor (FGFR1), which initiates signaling processes. The role of 6-O-sulfation is to 
interact with the FGFR, but not with FGF14. The dysfunction of 6-O-sulfation on HS has 
been linked with rheumatoid arthritis15, idiopathic hypogonadotropic hypogonadism16 and 
various cancers, as demonstrated in cell-based assays17–19.
Three isoforms of 6-OST are present in the human and mouse genomes. 6-OST isoform 1 
knockout is lethal to mice at the late embryonic stage, displaying systematic skeletal growth 
retardation, aberrant lung morphology, and reduced placental angiogenesis, whereas 6-OST 
isoform 2 knockout mice appear to be normal and fertile20. The cellular concentration of 6-
O-sulfation is influenced by expression levels of 6-OST and endoglucosamine-6-sulfatases 
which selectively hydrolyze the 6-O-sulfo group present in the highly sulfated domains of 
HS containing the disaccharide repeating unit -IdoA2S-GlcNS6S-21.
The biosynthesis of HS is a non-template driven biosynthetic process. The control of the 
structures of HS largely depends on the substrate specificity of each enzyme in the 
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biosynthetic pathway to ensure the structural consistency between iterations. Understanding 
how HS biosynthesis enzymes function and interact with their substrates plays an essential 
role in uncovering the cellular control of HS biosynthesis. Despite extensive efforts, 
crystallization of human and mouse isoforms of 6-OST was unsuccessful. Here, we report 
ternary complex crystal structures of zebrafish 6-OST isoform 3 as a maltose-binding 
protein (MBP) fusion protein (zf6-OST) at 1.95 – 2.1 Å resolutions in the presence of three 
different homogeneous HS oligosaccharide substrates and the cofactor product, 3′-
phosphoadenosine 5′-phosphate (PAP) (Figure.1, Figure 2 and Supplementary Table 1). The 
zf6-OST shows >70% sequence identity to the three human isoforms, offering a good model 
for understanding the functionality of the human orthologs. Based on these crystal 
structures, mutants were created and assayed against different oligosaccharide substrates to 
probe the roles of individual amino acids in catalysis and saccharide substrate recognition. 
This study reveals how 6-OST engages its substrate in an unpredicted orientation, defines 
key residues involved in substrate binding and catalysis, addresses substrate specificity 
between the three mammalian isoforms, and provides structural insight for mutants 
associated with human disease. As a result, several mutants were generated which may 




The catalytic domain (Lys75-Ser395) of zf6-OST was crystallized as an N-terminal MBP 
fusion protein in ternary complexes with the cofactor product PAP and three 
oligosaccharides (substrates I, II and III) (Figure 1, Figure 2 and Supplementary Figure 4). 
All three structures were solved in the same crystal form (Supplementary Table 1), 
containing two MBP-fusion molecules in the asymmetric unit (referred to as molecule A and 
molecule B), with each zf6-OST domain binding simultaneously to PAP and an 
oligosaccharide substrate (Supplementary Figure 2). The two zf6-OST domains in the 
asymmetric unit superimpose well with an RMSD of 0.46 Å over 287 Cα's (Supplementary 
Figure 2b). The largest difference is in the position of the extended-flexible C-terminal helix 
(helix 11). In molecule B, a few more residues can be modeled to weak electron density with 
the α-helix slightly unwound at residue Gln374 and its position stabilized by lattice 
contacts.
Despite limited sequence identity to catalytic domains of the other HS sulfotransferases 
(17% to the N-sulfotransferase domain of NDST-1, 16% to 3-OST-1, and 23% to 2-OST), 
the catalytic domain of zf6-OST retains elements of the canonical α/β sulfotransferase 
domain fold, consisting of a central four-stranded parallel β-sheet flanked on either side by 
α-helices (Figure 2a). At the heart of this domain is a 5'-phosphosulfate binding-loop 
consisting of a strand-loop-helix motif (β1–α2) involved in binding and proper positioning 
of the cofactor PAPS for catalysis. In addition, a conserved α-helix (α4) runs across the top 
of the substrate binding site interacting with both PAP and the saccharide substrate. Unique 
to zf6-OST is a 20 residue N-terminal coil that cradles the C-terminal helix and runs along 
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the N-terminal edge of the central β-sheet (Figure 2a, orange). The zf6-OST also contains 
five conserved disulfide bonds that are not found in the other HS sulfotransferases.
Protein-Substrate Interactions
Despite the substrates having three potential glucosamines that could bind in the active site, 
all three substrates bind in a similar orientation, with the nonreducing end GlcNS residue 
(residue 1) bound in the active site near the PAP (Figure 2, Supplementary Figure 3). 
Substrate II forms the same interactions with zf6-OST as substrate III however additional 
binding information can be obtained from the ternary structure of zf6-OST/PAP/substrate III 
due to the presence of an extra GlcA (0) on the nonreducing end of substrate III. Therefore, 
the subsequent analysis focuses on the binding of zf6-OST to substrate III (Figure 2a, b, and 
c). In this structure, the majority of interactions between zf6-OST and the substrates are with 
the acceptor GlcNS (1) and the adjacent disaccharide GlcA-GlcNS (residues 2 and 3) on the 
reducing side. The acceptor 6-hydroxyl group of GlcNS (1) lies 4.7 Å from the leaving 
group oxygen of the PAP molecule, displaying the anticipated orientations and distance 
between acceptor and donor groups for the in-line transfer of the sulfo group from PAPS 
(Figure 2b). Residue His158 forms a hydrogen bond with this 6-hydroxyl group, likely 
serving as the catalytic base for zf6-OST. In addition, the sidechain of Trp210 sits 
perpendicular to the face of GlcNS (1) and is also in position to form a hydrogen bond with 
the 6-hydroxyl group. The N-sulfo moiety of GlcNS (1) is within hydrogen bonding distance 
to backbone amides from both residues Thr209 and Trp210 and forms water mediated 
hydrogen bonds with Thr209 and Thr212. Residues Arg148 and Trp153 are both within 
hydrogen bonding distance of the carboxylate group from the adjacent GlcA (2). In addition, 
Lys131 may form a hydrogen bond with the carboxylate group. After GlcA (2), there is 
variability between the positions of the substrates with respect to the two molecules in the 
asymmetric unit (A and B) for each structure, and between the different substrates (Figures 
2c, and 2d, Supplementary Figure 2b). However, the key interactions between the protein 
and substrate II and III are similar in all cases: Lys131 is within hydrogen bonding distance 
to the 3-hydroxyl of the next GlcNS (3) sugar; Lys 132 is within hydrogen bonding distance 
to both sulfo moieties from GlcNS (3) and IdoA2S (4) residues. The protein displays no 
interactions with the saccharides at the 5th and 6th positions.
The nonreducing end GlcA residue of substrate III (0) also displays interactions with the 
protein, revealing how the enzyme interacts with substrates beyond the nonreducing end of 
the acceptor GlcN, as would be the case for a longer HS substrate. In molecule A of the 
asymmetric unit, there is no electron density for this saccharide, suggesting it is disordered. 
However, in molecule B, this saccharide is refined with an occupancy of ~ 75%, consistent 
with the partial difference density observed in the electron density omit map (Supplementary 
Figure 3c). In this position, the 2-hydroxyl is in position to form a hydrogen bond with 
Arg148, while the carboxylate can form a hydrogen bond with Arg206 (Figure 2b). 
Manually modeling an additional GlcNS on the nonreducing end of substrate III suggests 
the binding path for larger HS chains lies across the face of the enzyme, crossing over the 
PAP and effectively burying it within the active site (Supplementary Figure 4a). The N-sulfo 
moiety of the modeled GlcNS is in position to bind to Arg112, while the 6-hydroxyl group 
lies near residues Arg206 and Arg329. In all three crystal structures, a tartrate molecule is 
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observed in molecule B of zf6-OST at this position, forming salt bridges with Arg112 that 
potentially mimic the proposed interaction with the N-sulfo group on the modeled GlcNS 
(Supplementary Figure 4a).
Substrate I differs from II and III as it contains only GlcA. The binding position of substrate 
I is similar to that of II and III for sugar residues 1 thru 3 (Figure 2d). However, substrate I 
has a GlcA residue in position 4, causing changes in the substrate orientation since the GlcA 
is observed in the 4C1 conformation rather than the 2S0 skew boat conformation of the 
IdoA2S in substrates II and III (Figure 2d). In molecule A of zf6-OST/PAP/substrate I 
structure, Lys131 forms similar interactions with the GlcA (2) as with substrates II and III, 
while Lys132 is within hydrogen bonding distance to only the sulfo group of GlcNS (3) due 
to the substitution of GlcA for IdoA2S at residue 4. In molecule B of the substrate I ternary 
complex, Lys131 is mostly disordered and Lys132 points away from the oligosaccharide 
substrate (Figure 2d, Supplementary Figure 4b). In molecule B of all three structures, there 
is a small amount of density consistent with a low occupancy orientation of the saccharides 
from residue 3 to 6 that may represent 10–20% of the bound substrate. However, this 
orientation cannot be modeled accurately due to its low occupancy.
Comparison of zf6-OST to other HS Sulfotransferases
The binding orientation of these substrates to zf6-OST differs tremendously from structures 
of the other HS sulfotransferase/substrate complexes; 3-OST-1 and -3, and 2-OST. In these 
sulfotransferases, the saccharide substrates are bound in an open cleft that extends across the 
face of the enzyme perpendicular to the PAP molecule (Figure 3a, orange). However, this 
open cleft is occluded in zf6-OST by a coil containing residues Thr209 and Trp210 (Figure 
3a, cyan). Instead, the substrates bind to zf6-OST in an orientation perpendicular to that of 
the other HS sulfotransferases, likely passing over the co-factor, potentially burying PAPS 
within the active site (Figure 3a, green).
In spite of the differences in the global substrate binding orientation, the position of the key 
catalytic amino acid residues in the active sites and the orientation of the PAP and acceptor 
saccharide hydroxyl group from 2-OST and zf6-OST are remarkably similar (Figure 3b). 
Both 2-OST and zf6-OST appear to utilize a histidine residue as a general base with a Lys 
residue from the 5'-phosphosulfate binding loop assisting in catalysis. This differs from the 
NDST-1 and 3-OST isoforms that utilize a glutamate as their catalytic bases10, 13, 22. The 
position of the acceptor 6-hydroxyl from the GlcNS (1) (acceptor residue for zf6-OST) and 
the 2-hydroxyl of IdoA (acceptor residue for 2-OST) superimpose perfectly in the active site 
and are found within hydrogen bonding distance to their proposed catalytic bases (Figure 
3b). This conservation in active site geometry and key catalytic residues suggests that these 
enzymes utilize a similar mechanism.
The different binding orientation of substrate may allow 6-OST to exhibit a more relaxed 
substrate specificity than either the 2-OST or 3-OSTs, with regards to length, sequence and 
sulfation. 6-OST can utilize substrates as short as trisaccharides and sulfates both GlcNS and 
GlcNAc residues surrounded by GlcA, IdoA as well as IdoA2S residues, although the 
susceptibility of GlcNAc to 6-OST modification is somewhat lower23. 2-OST demonstrates 
a higher level of specificity, requiring at least a pentasaccahride with N-sulfation, but 
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excluding substrates with 6-O-sulfation13, 24. 3-OST demonstrates the greatest substrate 
specificity among HS sulfotransferases, requiring at least a tetrasaccharide with specific 
saccharide sequences and sulfation patterns within adjacent residues23, 25. Furthermore, 6-
OST is the only HS sulfotransferase that transfers the sulfo group to a primary alcohol; 
whereas 2-OST and 3-OST sulfate secondary alcohols. The fact that 6-OST sulfates a 
primary hydroxyl allows the bulk of the substrate to sit an additional bond length away from 
the active site (Figure 3b), potentially reducing the number of sugar residues that come in 
contact with the protein. Thus, the distinct substrate binding orientation in 6-OST may allow 
the enzyme to be more promiscuous, consequently generating a larger pool of diverse HS 
products for interaction with a wider variety of target proteins.
Mutagenesis Analysis
Site-directed mutagenesis experiments were conducted to determine the contribution of 
individual residues to catalysis and substrate recognition for zf6-OST using five specially 
designed oligosaccharide substrates (substrates IV, V, VI, VII and VIII (Figure 1b)). To 
match the mutagenesis work with the crystallography, oligosaccharides were synthesized 
that only allowed for sulfation at the nonreducing end GlcN site by placement of sulfo 
groups on the 6-hydroxyls of the remaining GlcN.
Wild type (WT) zf6-OST exhibits different levels of activity towards substrate IV to VIII 
(Table 1). Among them, the least reactive substrate is substrate VI (contains a GlcNAc 
residue at the acceptor), and the most reactive substrate is VIII (GlcNS residue as the 
acceptor), consistent with the fact that 6-OSTs are more reactive towards GlcNS than 
GlcNAc. This observation correlates with the structures, since zf6-OST forms extensive 
interactions with the N-sulfo group via residues Thr209, Trp210 and Thr212 (Figure 2b).
The relative activities of the mutants towards these substrates were also measured and 
normalized to levels exhibited by the wildtype enzyme (Table 1). Mutations of amino acid 
residues within the active site significantly reduced the activities to all tested substrates 
(Table 1). Mutant zf6-OSTs H101A and K104A displayed 20- to 100-fold reduction in the 
sulfotransferase activity towards substrates IV to VII. In the crystal structures, these 
residues interact with the 5′-phosphate of the PAP molecule, suggesting involvement in PAP 
binding and/or stabilization of the transition state (Figure 2b). Based on the crystal structure, 
His158 is the proposed catalytic base and directly interacts with the 6-OH acceptor of 
GlcNS (1). As expected, the H158A mutant displays no enzymatic activity. Mutants W210A 
and H203A also displayed significant reduction in the activity, as these two residues interact 
with GlcNS (1) and are likely involved in properly orienting the acceptor for catalysis 
(Figure 2b).
Mutational analysis revealed intriguing molecular interactions pertaining to substrate 
recognition. Based on the structures with substrates II and III, Lys132 has a unique role in 
the substrate recognition by interacting with an IdoA2S (4) on the reducing side of the 
acceptor GlcNS (1). Mutants K132A and K131A/K132A reduced the activities to substrates 
IV to VII (containing IdoA2S) to 4 to 8% of that for wt zf6-OST. Furthermore, substitution 
of Lys132 with a negatively charged amino acid residue (K132E) had an even more 
profound impact on substrate reactivity than that of the substitution with a neutral amino 
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acid residue (K132A). However, using a substrate (substrate VIII) with no IdoA2S residues, 
we found that the mutants maintained 91% and 28% reactivity for K132A and K132E, 
respectively. These observations support the role of K132 in enhancing binding of substrates 
containing IdoA2S, mediated by interaction with the 2-O-sulfo group (Figure 2b and 2c). 
The lower activity for the K132E vs K132A mutant on substrate VIII is likely due to 
repulsion with the neighboring NS group on GlcN (3).
Several mutants, including K202E, R112E, R116E and R329E, displayed different degrees 
of increased activity compared with wt zf6-OST. The increase is particularly profound 
towards Substrate VI. For example, the activity of R112E was 7-fold higher than that for the 
wild type protein. The side chain of Arg112, as well as other amino acid residues in this 
group, possibly interacts with saccharide substrates beyond the nonreducing end of the 
acceptor GlcN (1) present in the crystal structures (Figure 2b and Supplementary Figure 4a). 
Interactions with wild type residues may exhibit a negative impact on the activity when the 
acceptor is a GlcNAc residue, a known poor substrate for 6-OST. For substrate VI, GlcNS6S 
residues may compete for binding to the acceptor site placing other GlcN residues near 
Arg112 (modeled GlcNS, Supplementary Figure 4a) thus inhibiting productive binding. The 
R112A mutation could reduce this interaction while R112E would repel binding in this 
orientation allowing for more substrate to bind with the acceptor GlcNAc group in the active 
site. This effect would be reduced for substrates with GlcNS acceptor residues (substrates IV 
and V) as the –NS group would have enhanced binding to the active site via the hydrogen 
bonding network to residues T209, W210 and T212 as well as substrate VII due to the 
additional interactions with the GlcA on the nonreducing end.
Substrate Specificity of 6-OST Isoforms
6-OST is present in three different isoforms in the human genome. The zf6-OST shares 
71%, 72% and 81% sequence identities with the human 6-OST isoforms 1, 2 and 3, 
respectively (Figure 4). Whether different 6-OST isoforms display distinct substrate 
specificities has been controversial. Previous reports using mouse 6-OSTs and 
heterogeneous polysaccharide substrates suggested these enzymes have different but 
somewhat overlapping substrate preferences26. In contrast, later work observed that these 
enzymes have “qualitatively similar substrate specificities, with minor differences in target 
preferences27.” To confirm the substrate specificity between isoforms, we measured the 
reactivity of m6-OST-1, h6-OST-2 and h6-OST-3 towards five oligosaccharide substrates IV 
to VIII. Our results show very similar trends of selectivity towards substrates IV to VIII 
(Supplementary Table 2). For example, Substrate VIII is the most reactive substrate and 
Substrate IV is the least reactive substrate for all isoforms. The data suggest that with the 
substrates tested, there are no major difference in substrate specificities among isoforms. 
This conclusion is also supported by the crystal structure. Mapping of conserved residues of 
the human 6-OST isoforms onto the zf6-OST structure reveals that all residues that interact 
with HS in these structures and surround the HS binding pocket are totally conserved in all 
three human isoforms (Figure 3c). The major sequence differences between the enzymes 
reside in the partially disordered C-terminal tail extending away from the catalytic domain, 
distal from the substrate binding site in the crystal structures.
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6-OST is a critical enzyme in the HS biosynthetic pathway producing 6-O-sulfated GlcN 
residues in HS to display various biological functions. Mutations in h6-OST-1 have been 
associated with idiopathic hypogonadotrophic hypogonadism (IHH), a genetic disease 
manifested by delayed or lack of puberty16. Mutations R306W, R306Q, R323Q, R382W and 
M404V in 6OST-1 were reportedly found in some IHH patients16. In a study by Tornberg et 
al, all four mutants exhibited modest reduction in sulfotransferase activity in an in vitro 
assay16. Three of the four disease-related residues (except M404) are conserved in zf6-OST 
and map to the structure, providing some insight for the reduction in their activity (Figure 3d 
and Fig 4.). Most notable is the R323Q mutation, which is equivalent to Arg329 in zf6-OST. 
Tornberg and colleagues suggested that Arg323 may interact with an O-sulfo moiety from 
HS. The zebrafish equivalent (Arg329) is located in the substrate binding pocket near the 
nonreducing end of substrate III. Modeling an additional GlcNS on to the end of substrate 
III positions the 6-hydroxyl of the modeled GlcNS in close proximity to Arg329 
(Supplementary Figure 4a). Based on the modeling, it is plausible that this Arg residue could 
interact with a 6-O-sulfo group on HS, possibly contributing to creation of contiguously 6-
O-sulfated NS domains. This is supported by Tornberg et al's in vitro work which displayed 
a reduction in activity for R323Q against HS but maintained similar activity to wild type 
enzyme for substrate lacking 2-O- and 6-O- sulfo groups. In our mutational analysis, R329A 
of zf6OST-3 has very similar sulfotransferase activity to that of wild type protein (Table 1). 
This result is somewhat unsurprising as this residue does not interact with our substrates 
(based on the crystal structures) due to the lack of an extended nonreducing end in the 
synthesized substrates. To prove this hypothesis, a series of specially designed 
oligosaccharide substrates would be required. The synthesis of the oligosaccharide 
substrates with the GlcNS6S residue at the nonreducing end but GlcNS residue at the 
reducing end is currently beyond our synthetic capability. Zebrafish residue Arg312 (human 
Arg306) is found in the catalytic core away from the substrate binding site and forms a 
hydrogen bond with Glu372 (human Glu366) of the C-terminal α-helix 11 suggesting it is 
not involved in binding substrate, but potentially affects enzyme stability. Arg388 (human 
Arg382) is found at the very C-terminus of our structure far from the active site, and forms 
no interaction with the rest of the protein (Figure 3d). This makes it difficult to interpret 
possible effects of the R382W mutation on activity and disease.
Improving Chemoenzymatic Synthesis of HS
A cost-effective method to prepare diversified HS oligosaccharides with different sulfation 
patterns is critical for developing HS-based therapeutics with high specificity for different 
targets. One particular example is to prepare synthetic heparins for anticoagulant therapy28. 
The chemoenzymatic method which utilizes 6-OST is becoming a promising approach to 
synthesize structurally defined HS oligosaccharides29. The structure of zf6-OST revealed 
potential locations to engineer amino acid changes for synthesis of specific HS 
oligosaccharides. For example, mutant K132E effectively sulfates the substrates containing 
GlcA, but has very low reactivity towards IdoA2S-containing oligosaccharides. The K132 
mutants offer the possibility to engineer the substrate specificity of zf6-OST for synthesis of 
oligosaccharides containing GlcA residues, but no IdoA2S residues, around the modification 
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site. In addition, several mutants, K202E, R112E, R116E and R329E, were identified to 
display significantly increased activity towards GlcNAc residues. These serendipitous 
mutations provide new tools to generate greater yields of GlcNAc6S-containing saccharides. 
Thus, in addition to expanding our general knowledge of the HS biosynthesis pathway, the 
results from this study clearly provide the structural information to engineer 6-OST with 
expanded capability to synthesize HS based therapeutics.
Methods
Crystallization/Structure Determination
Zf6-OST was expressed and purified as a fusion with the maltose binding protein as 
described in the Supporting Information. Crystals of zf6-OST in the presence of 10 mM 
substrate II were grown by hanging drop vapor diffusion with 2 μl of protein solution at 13 
mg ml−1 and 2 μl of reservoir solution containing 100 mM Tris pH 7.5, 200 mM disodium 
tartrate and 18–19% PEG3350 (w/v) at 20° C. Crystals containing substrates I and III were 
grown by streak-seeding hanging drops of zf6-OST with 10mM of substrate I or III with 
seeds from crystals of protein with substrate II at 20° C. For data collection, 1–2 μl of 
cryoprotectant solution(100 mM Tris pH 7.5, 125 mM NaCl, 200mM disodium tartrate, 21% 
PEG3350 (w/v), 1 mM PAP, 4 mM maltose, 15% ethylene glycol (v/v) and 1 mM of the 
appropriate substrate (I, II, or III), was added to the crystallization hanging drop. The 
crystals were then transferred directly to cryoprotectant solution and flash frozen in liquid 
nitrogen. Data were collected at the Southeast Regional Collaborative Access Team (SER-
CAT) 22-ID beamline at the Advanced Photon Source, Argonne National Laboratory at a 
wavelength of 1.0 Å. All data were processed with HKL200030. To solve the structure of 
zf6-OST with substrate II present, molecular replacement was carried out in Phenix31 with 
Phaser32 using a model of MBP (PDB code 3DM0) along with a trimmed polyalanine model 
of 2-OST (PDB code 3F5F) containing only well conserved secondary structure. The 
structure was refined in Phenix using Cartesian simulated annealing, positional, ADP 
refinement, and manual model building in Coot33, 34. The structures of zf6-OST containing 
substrates II and III were subsequently solved using the structure of zf6-OST with substrate 
II. The same Rfree flagged reflections were maintained for all three data sets. The structures 
possessed good geometry, with all three structures having greater than 97.8% of the residues 
in the Ramachandran favored region, with ≤ 0.1% outliers and overall refinement scores of ≤ 
1.1, as assessed by MolProbity35 (Supplementary Table 1).
Preparation of 6-OSTs Mutants and Isoforms
Mutants were generated on the pMALX MBP-fusion zf6-OST construct used for 
crystallization, using QuikChange (Agilent) mutagenesis. The mutant plasmids were 
confirmed by DNA sequencing analysis. The resultant mutants were expressed and purified 
in 1L scale following the same protocol as used for the wild type protein. Mammalian 
isoforms of mouse 6-OST-1 and human 6-OST isoforms 2 and 3 were expressed and purified 
from SF9 insect cells and is described in detail in the Supporting Information.
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Determination of the Enzymatic Activity of zf6-OST Mutants and Mammalian Isoforms
The synthesis of substrates were completed according to the chemoenzymatic method 
published previously36, 37 and are described in more detail in Supporting Information. 
Activity measurement for wildtype and mutant proteins were carried out by incubating 1 μg 
of wildtype or mutant zf6-OST with 0.1 nmol of substrate (IV to VIII) and 1 × 105 cpm of 
[35S]PAPS (0.1nmol) in 100 μL of buffer containing 50 mM MES, pH 7.2 at 37 °C for 2.5 
hours. Reactions were quenched by the addition of 6 M urea and 100 mM EDTA then 
subjected to a 200-μL DEAE-Sepharose chromatography to purify the 35S-labeled 
oligosaccharide. The quantity of [35S] sulfated oligosaccharide was determined by liquid 
scintillation counting. The negative control contained all of the components without enzyme.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Structures of oligosaccharides used in this study. a) Chemical structures of oligosaccharides 
used in the crystallization experiments. The acceptor GlcNS residue found in the active site 
of zf6-OST is depicted in a blue box. The IdoA2S residue (4) in substrate II and III is 
presented in the 2SO skew boat conformation as found in the co-crystal structures. b) 
Chemical structures of oligosaccharides used to probe substrate specificities of mutants. The 
6-O-sulfation site in each substrate is circled. The IdoA2S residue in substrate IV to VII is 
presented in 1C4 conformation. Representative electrospray ionization mass spectrometry 
spectra are shown in Supplementary Figure 5. The abbreviated sequences for each substrate 
is: Substrate I (6-mer), GlcNS-GlcA-GlcNS-GlcA-GlcNS-GlcA-pNP; Substrate II (6-mer), 
GlcNS-GlcA-GlcNS-IdoA2S-GlcNS-GlcA-pNP; Substrate III (7-mer), GlcA-GlcNS-GlcA-
GlcNS-IdoA2S-GlcNS-GlcA-pNP; Substrate IV (8-mer), GlcNS-GlcA-GlcNS6S-IdoA2S-
GlcNS6S-IdoA2S-GlcNS6S-GlcA-pNP; Substrate V (9-mer), GlcA-GlcNS-GlcA-GlcNS6S-
IdoA2S-GlcNS6S-IdoA2S-GlcNS6S-GlcA-pNP; Substrate VI (8-mer), GlcNAc-GlcA-
GlcNS6S-IdoA2S-GlcNS6S-IdoA2S-GlcNS6S-GlcA-pNP; Substrate VII (9-mer), GlcA-
GlcNAc-GlcA-GlcNS6S-IdoA2S-GlcNS6S-IdoA2S-GlcNS6S-GlcA-pNP; Substrate VIII 
(9-mer), GlcA-GlcNS-GlcA-GlcNS6S-GlcA-GlcNS6S-GlcA-GlcNS6S-GlcA-pNP.
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Crystal structure of zf6-OST. a) Catalytic domain of zf6OST (blue) with substrate III 
(green) and the cofactor product PAP (magenta) bound to the active site of molecule B. 
Disulfide bonds are displayed in yellow and the N-terminal tail unique to the zf6-OST 
enzymes is shown in orange. The C-terminal α-helix extending away from the subdomain 
structure has been cropped in this image. b) Interactions between substrate III and zf6-OST. 
Hydrogen bonds between substrate III or PAP and zf6-OST are shown in dashed black lines. 
Waters are shown as red spheres. A red asterisk marks the acceptor 6-hydroxyl. c) 
Superposition of molecules A (gray) and B (blue) of zf6-OST in the asymmetric unit with 
substrate III bound. Hydrogen bonds between molecule A and B and their respective 
substrates (white and green respectively) are displayed as pink and black dashed lines 
respectively. D) Superposition of zf6-OST binding substrate I (pink) with substrate III 
(protein in blue, substrate green) in molecule B for each structure. The SDS-PAGE gel 
picture of zf6-OST is shown in Supplementary Figure 6.
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Structural analysis of the zf6-OST crystal structure. a) Superposition of the crystal structure 
of 2-OST (gray, PDB code:4NDZ) with bound substrate (orange) with zf6-OST (blue) with 
substrate III (green). The loop in zf6-OST that blocks the substrate channel in other HS 
sulfotransferases is colored cyan. b) Superposition of catalytic active site residues and 
acceptor saccharide residues of 2-OST and zf6-OST with hydrogen bonds shown (pink and 
black respectively). c) Conserved residues between human 6-OST-1, 2, and 3 isoforms 
mapped onto the structure of the catalytic domain of zf6-OST with bound substrate III 
(green). Residues that are totally conserved are colored gray, residues conserved between 
isoforms 1 and 2 are shown colored cyan, 1 and 3 in pink and 2 and 3 in orange. Residues 
that differ in all isoforms are colored purple. d) Positions of mutations (cyan) found in IHH 
patients mapped onto the zf6-OST structure with bound substrate III. Numbering is for the 
human 6-OST-1 enzyme.
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Alignment of catalytic domain sequences from zf6-OST with that of the three human 
isoforms h6-OST-1, -2, and -3. Secondary structural elements from the crystal structure are 
displayed above the sequence with β-strands depicted as blue arrows and α-helices depicted 
as teal rectangles. Conserved catalytic residues are colored red, His101 which may stabilize 
the transition state is colored blue, residues that interact with the oligosaccharides in the 
crystal structure are green, and residues that could possibly form additional interactions with 
longer substrates are colored magenta. Missense mutations suggested to contribute to 
idiopathic hypogonadotropic hypogonadism (IHH) are boxed in cyan. N-terminal region is 
boxed in orange.
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Table 1











WT 100 ± 3.0%
f 100 ± 6.5% 100 ± 31% 100 ± 8.6% 100 ± 3.7%
Relative activity 
to substrate IV - 85% 17% 41% 149%
Catalytic Active Site 
Residues
H101A 1.3 ± 0.2% 1.0 ± 0.1% 2.5 ± 0.2% 1.2 ± 0.5% ND
g
K104A 2.8 ± 0.7% 3.8 ± 0.4% 5.1 ± 1% 3.0 ± 0.2% ND
g
H158A 0.3 ± 0.2% 0.3 ± 0.0% 1.2 ± 0.5% 0.4 ± 0.0% ND
g
H203A 10 ± 0.1% 9.8 ± 0.5% 13 ± 2.1% 7.9 ± 0.5% ND
g




K131A 62 ± 9.0% 37 ± 2.2% 35 ± 4.6% 35 ± 0.7% ND
g
K132A 8.0 ± 0.2% 4.4 ± 0.1% 6.4 ± 0.7% 4.3 ± 0.3% 91 ± 15%
K132E 0.9 ± 0.0% 0.9 ± 0.0% 2.3 ± 0.5% 1.0 ± 0.2% 28 ± 6.4%
K131A/K132A 2.4 ± 0.2% 1.6 ± 0.4% 2.9 ± 0.2% 1.4 ± 0.1% 80 ± 4.5%
R148A 17 ± 0.2% 46 ± 1.7% 9.5 ± 0.4% 12 ± 0.3% ND
g
W153A 34 ± 1.1% 41 ± 1.7% 40 ± 2.4% 86 ± 10.4% ND
g
R206A 163 ± 16% 70 ± 3.3% 126 ± 21% 33 ± 8.6% 100 ± 3.2%
R206E 110 ± 25% 155 ± 4.0% 497 ± 13% 87 ± 1.6% ND
g
Potential Nonreducing End 
HS Binding Residues
K202A 132 ± 1.5% 101 ± 3.9% 85 ± 3.4% 114 ± 0.7% 100 ± 1.4%
K202E 110 ± 25% 155 ± 4% 497 ± 13% 87 ± 1.6% ND
g
R112A 127 ± 2.6% 206 ± 3.9% 310 ± 27% 276 ± 17% ND
g
R112E 109 ± 11% 194 ± 12% 700 ± 17% 349 ± 27% ND
g
R116A 130 ± 6.8% 191 ± 3.9% 305 ± 39% 231 ± 24% ND
g
R116Q 136 ± 1.0% 173 ± 4.4 % 231 ± 15% 228 ± 45% ND
g
R116E 125± 5.4% 204 ± 0.4% 512 ± 109% 337 ± 6.3% ND
g
R329A 159 ± 12% 141 ± 2.3% 144 ± 9.2% 165 ± 0.3% 103 ± 0.0%
R329E 144 ± 4.3% 150 ± 26% 450 ± 75% 263 ± 15% ND
g
a
The reactivity of wild type enzyme to substrate IV is 8,368 ± 918 pmol mg protein−1 h−1 (n =6).
b
The reactivity of wild type enzyme to substrate V is 7,088 ± 1,403 pmol mg protein−1 h−1 (n =6).
c
The reactivity of wild type enzyme to substrate VI is 1,415 ± 223 pmol mg protein−1 h−1 (n = 6).
d
The reactivity of wild type enzyme to substrate VII is 3,460 ± 282 pmol mg protein−1 h−1 (n = 6).
e
The reactivity of wild type enzyme to substrate VIII is 12,514 ± 3,949 pmol mg protein−1 h−1 (n = 4).
f
The values for activity for each mutant are normalized to levels exhibited by the wildtype enzyme, and represent the mean ± standard deviation.
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Not determined
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